Sacubitril/Valsartan

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Coronary Artery DiseaseEssential HypertensionMitral RegurgitationHfpef

114 competitors in Coronary Artery Disease

#DrugCompanyPhaseTrials

1

Adempas

Bayer

Approved

—2

Lopid

Pfizer

Approved

—3

Adenocard

Astellas

Approved

—4

Jardiance

Boehringer Ingelheim

Approved

25

Pletal

Otsuka

Approved

16

Colcrys

Jazz Pharmaceuticals

Phase 3

47

Cyklokapron

JJ Molner

Approved

—8

Inomax

MMallinckrodt

Approved

—9

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

—10

Osmitrol

BB. Braun Medical Inc.

Approved

—Show 37 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Heart Failure16 trials

Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India

Completed·Novartis··NCT04735354·268 enrolled

A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study

Completed·Novartis·Phase 3·NCT06149104·8 enrolled

Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction

Unknown status·MMethodist Health System··NCT05168787·352 enrolled

Show 13 more trials

Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction

Recruiting·KKafrelsheikh University·N/A·NCT07192341·220 enrolled

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

Unknown status·—··NCT04743063·40,000 enrolled

Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.

Completed·—··NCT04736433·6,066 enrolled

Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure

Completed·Novartis··NCT05613140·9,230 enrolled

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

Terminated·Novartis·Phase 2·NCT06142383·136 enrolled

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

Completed·Novartis··NCT03387163·402 enrolled

PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

Completed·Novartis··NCT02957409·1,009 enrolled

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

Completed·Novartis··NCT05096143·42,269 enrolled

Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure

Unknown status·UUnity Health Toronto·N/A·NCT04107220·300 enrolled

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

Completed·Novartis··NCT05096039·1,614,719 enrolled

Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL.

Completed·Novartis··NCT05448872·924 enrolled

Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction

Completed·NNational Institute of Cardiovascular Diseases, Pakistan·Phase 4·NCT05387967·121 enrolled

Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

Completed·Novartis·Phase 4·NCT02554890·887 enrolled

Hypertension3 trials

A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension

Completed·Novartis·Phase 2·NCT01870739·115 enrolled

Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension

Unknown status·LLanZhou University·N/A·NCT04800081·264 enrolled

Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT05545059·138 enrolled

Hypertrophic Cardiomyopathy2 trials

Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 2/3·NCT05366101·168 enrolled

Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy

Completed·NNewcastle University·Phase 2·NCT03832660·168 enrolled

Essential Hypertension2 trials

Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy

Not yet recruiting·SSichuan Academy of Medical Sciences·Phase 4·NCT06501651·297 enrolled

QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

Not yet recruiting·WWuhan Createrna Science and Technology Co., Ltd·Phase 3·NCT06716970·810 enrolled

HFpEF2 trials

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Completed·Novartis·Phase 3·NCT03988634·467 enrolled

Enhancing the Natriuretic Peptide System in HFpEF

Enrolling by invitation·HHorng Chen·Phase 1/2·NCT05279742·60 enrolled

15 more indications

Treatment2 trials

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

Recruiting·HHeart Center Research, LLC·Phase 4·NCT06218199·80 enrolled

Early Treatment of ARNI on Myocardial Remodeling and Progress

Unknown status·RRenJi Hospital·Phase 4·NCT04342351·280 enrolled

Left Ventricular Hypertrophy1 trial

Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT04929600·120 enrolled

Pediatric Patients1 trial

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Completed·Novartis·Phase 3·NCT03785405·216 enrolled

Breast Cancer1 trial

Prevention of Cardiac Dysfunction During Breast Cancer Therapy

Completed·TTorbjorn Omland·Phase 2·NCT03760588·138 enrolled

Dialysis Patients1 trial

Sacubitril/Valsartan for CKD5 Stage Dialysis Patients

Completed·RRuijin Hospital·Phase 4·NCT05243199·330 enrolled

Double-blind1 trial

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

Completed·Novartis·Phase 3·NCT03066804·2,572 enrolled

Endothelial Function1 trial

Comparing ARNI With ACE Inhibitor on Endothelial Function

Withdrawn·—·Phase 4·NCT03119623

Mortality1 trial

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

Completed·Novartis·Phase 4·NCT04023227·918 enrolled

Mitral regurgitation1 trial

ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling

Recruiting·RRehab Werida··NCT07379788·180 enrolled

Physical Activity1 trial

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

Completed·Novartis·Phase 4·NCT02970669·140 enrolled

Metabolism1 trial

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

Suspended·UUniversity of Pennsylvania·Phase 3·NCT03508739·25 enrolled

ALS1 trial

Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

Terminated·—·Phase 4·NCT02788656·4 enrolled

Coronary Artery Disease1 trial

Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

Recruiting·CChina National Center for Cardiovascular Diseases·Phase 4·NCT06917664·220 enrolled

Systolic Dysfunction1 trial

The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI

Completed·NNHS Greater Glasgow and Clyde·Phase 3·NCT03552575·93 enrolled

Unspecified1 trial

Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)

Withdrawn·Novartis·Phase 3·NCT04637555

Details

Drug Info

Related News